'For the quarter ending March 2024, standalone net sales (including other operating income) of Sanofi India has declined 0.56% to Rs 732.40 crore compared to quarter ended March 2023.  Operating profit margin has declined from 31.22% to 29.89%, leading to 4.78% decline in operating profit to Rs 218.90 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 18.46% to 23.62%.   Purchase of finished goods cost fell from 26.74% to 6.71%.   Employee cost increased from 11.65% to 15.18%.   Other expenses rose from 13.98% to 18.52%.   

Other income fell 74.81% to Rs 6.5 crore.  PBIDT fell 11.85% to Rs 225.4 crore.  Provision for interest remained nil.  

PBDT fell 11.86% to Rs 225.1 crore.  Provision for depreciation rose 3.09% to Rs 10 crore.  

Profit before tax down 12.45% to Rs 215.10 crore.  Provision for tax was expe...

Pleaselogin & subscribe to view the full report.

More Reports

• 

  (01-Mar-2025)

  Foseco India

  OP up 17%
• 

  (28-Feb-2025)

  Schaeffler India

  Maintains double digit revenue growth and stable OPM
• 

  (28-Feb-2025)

  Sanofi India

  OP up 18.78%
• 

  (28-Feb-2025)

  KSB

  Net up 33% largely on higher sales, higher OI and lower taxation